Published in J Clin Psychiatry on June 15, 2010
Pregnenolone in the Management of Schizophrenia Patients | NCT00174889
Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res (2010) 1.52
The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav (2010) 1.16
A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol (2012) 1.04
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull (2011) 0.97
Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice. PLoS One (2012) 0.90
Pregnenolone activates CLIP-170 to promote microtubule growth and cell migration. Nat Chem Biol (2013) 0.84
A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. Neuropsychopharmacology (2014) 0.82
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology (Berl) (2014) 0.81
GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism. Schizophr Res (2014) 0.79
Potential Role of Oestrogen Modulation in the Treatment of Neurocognitive Deficits in Schizophrenia. CNS Drugs (2016) 0.78
Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials. Mediators Inflamm (2016) 0.76
A role for picomolar concentrations of pregnenolone sulfate in synaptic activity-dependent Ca2+ signaling and CREB activation. Mol Pharmacol (2014) 0.76
Pregnenolone sulfate as a modulator of synaptic plasticity. Psychopharmacology (Berl) (2014) 0.76
The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders. Oncotarget (2015) 0.76
Brief report: an open-label study of the neurosteroid pregnenolone in adults with autism spectrum disorder. J Autism Dev Disord (2014) 0.76
Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice. Mol Psychiatry (2017) 0.75
A mathematical model of dysfunction of the thalamo-cortical loop in schizophrenia. Theor Biol Med Model (2014) 0.75
Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. Oncotarget (2016) 0.75
Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci (2006) 5.15
International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord (2014) 4.10
Psychiatric disorders and intellectual functioning throughout development in velocardiofacial (22q11.2 deletion) syndrome. J Am Acad Child Adolesc Psychiatry (2009) 2.74
Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry (2014) 2.15
Musical hallucinations: prevalence in psychotic and nonpsychotic outpatients. J Clin Psychiatry (2004) 1.70
Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab (2006) 1.69
Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry (2004) 1.55
Effect of implementing dental services in Israeli psychiatric hospitals on the oral and dental health of inpatients. Psychiatr Serv (2009) 1.51
Reboxetine as an optional treatment for hyperkinetic conduct disorder: a prospective open-label trial. J Child Adolesc Psychopharmacol (2005) 1.44
Itching in the psychiatric ward. Acta Derm Venereol (2008) 1.43
Preferential aggregation of obsessive-compulsive spectrum disorders in schizophrenia patients with obsessive-compulsive disorder. Can J Psychiatry (2006) 1.43
High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. J Clin Psychopharmacol (2002) 1.40
Double-Blind, Randomized, Placebo-Controlled Trial of Metoclopramide for Hypersalivation Associated With Clozapine. J Clin Psychopharmacol (2016) 1.39
Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clin Neuropharmacol (2013) 1.39
Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry (2003) 1.24
The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol (2005) 1.24
Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study. Int Psychogeriatr (2002) 1.24
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry (2002) 1.21
Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome. Am J Med Genet B Neuropsychiatr Genet (2004) 1.20
Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res (2005) 1.20
Effects of climate on admission rates of schizophrenia patients to psychiatric hospitals. Eur Psychiatry (2005) 1.19
Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J Mol Neurosci (2005) 1.19
Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs (2004) 1.16
An integrative quantitative model of factors influencing the course of anorexia nervosa over time. Int J Eat Disord (2009) 1.15
Risk factors and the evolution of psychosis in 22q11.2 deletion syndrome: a longitudinal 2-site study. J Am Acad Child Adolesc Psychiatry (2013) 1.10
Association of the low-activity COMT 158Met allele with ADHD and OCD in subjects with velocardiofacial syndrome. Int J Neuropsychopharmacol (2006) 1.09
Fear thou not: activity of frontal and temporal circuits in moments of real-life courage. Neuron (2010) 1.09
Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies. Isr J Psychiatry Relat Sci (2007) 1.07
Lenin's malady. Hum Pathol (2013) 1.07
Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol (2004) 1.05
Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry (2003) 1.05
Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder. Eur Neuropsychopharmacol (2005) 1.05
Cancer in schizophrenia: is the risk higher or lower? Schizophr Res (2005) 1.05
Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol (2006) 1.04
Heart rate variability in patients with major depression. Psychosomatics (2004) 1.04
Differences in audiovisual integration, as measured by McGurk phenomenon, among adult and adolescent patients with schizophrenia and age-matched healthy control groups. Compr Psychiatry (2008) 1.02
Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. Eur Neuropsychopharmacol (2007) 1.02
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry (2002) 1.01
Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS. Int J Neuropsychopharmacol (2007) 1.00
Multi-modal weight control intervention for people with persistent mental disorders. Psychiatr Rehabil J (2008) 1.00
Obstetric complications in individuals diagnosed with autism and in healthy controls. Compr Psychiatry (2005) 1.00
The impact of mental illness on sexual dysfunction. Adv Psychosom Med (2008) 1.00
Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int J Oncol (2008) 1.00
Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors. J Mol Neurosci (2004) 0.99
Expressed emotion: relevance to rehospitalization in schizophrenia over 7 years. Schizophr Bull (2005) 0.99
The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression. J Mol Neurosci (2011) 0.99
Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry (2006) 0.98
Alterations in QT dispersion in the surface electrocardiogram of female adolescent inpatients diagnosed with bulimia nervosa. Compr Psychiatry (2009) 0.98
Impaired procedural learning in obsessive-compulsive disorder and Parkinson's disease, but not in major depressive disorder. Behav Brain Res (2005) 0.98
Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes. Pediatr Res (2009) 0.97
Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases. Mol Cell Neurosci (2007) 0.97
Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. Oncol Rep (2006) 0.96
Enhanced maternal origin of the 22q11.2 deletion in velocardiofacial and DiGeorge syndromes. Am J Hum Genet (2013) 0.96
Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl) (2007) 0.96
Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol (2007) 0.95
Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol Sci (2003) 0.95
The relevance of neurosteroids to clinical psychiatry: from the laboratory to the bedside. Eur Neuropsychopharmacol (2005) 0.95
Does a clerkship in psychiatry contribute to changing medical students' attitudes towards psychiatry? Acad Psychiatry (2008) 0.95
Memantine for treatment-resistant OCD. Am J Psychiatry (2005) 0.95
Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications. Compr Psychiatry (2011) 0.95
Demographic and clinical characteristics of motor vehicle accident victims in the community general health outpatient clinic: a comparison of PTSD and non-PTSD subjects. Depress Anxiety (2007) 0.94
Nicotine dependence, abuse and craving: dimensionality in an Israeli sample. Addiction (2011) 0.94
Association between tobacco smoking and bipolar affective disorder: clinical, epidemiological, cross-sectional, retrospective study in outpatients. Compr Psychiatry (2011) 0.94
Effects of early-life stress on behavior and neurosteroid levels in the rat hypothalamus and entorhinal cortex. Brain Res Bull (2005) 0.93
Predictors of quality of life in major psychoses: a naturalistic follow-up study. J Clin Psychiatry (2003) 0.93
Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol (2003) 0.93
Genotype-phenotype correlation in 22q11.2 deletion syndrome. BMC Med Genet (2012) 0.92
Peripheral-type benzodiazepine receptor density and in vitro tumorigenicity of glioma cell lines. Biochem Pharmacol (2004) 0.92
Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol (2003) 0.92
Alcohol use disorders and perceived drinking norms: ethnic differences in Israeli adults. J Stud Alcohol Drugs (2012) 0.92
Shared obsessive-compulsive disorder: broadening the concept of shared psychotic disorder. Aust N Z J Psychiatry (2010) 0.92
Neuroimaging communality between schizophrenia and obsessive compulsive disorder: a putative basis for schizo-obsessive disorder? World J Biol Psychiatry (2003) 0.91
Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. J Affect Disord (2011) 0.91
Childhood adversity moderates the effect of ADH1B on risk for alcohol-related phenotypes in Jewish Israeli drinkers. Addict Biol (2013) 0.91
Velo-Cardio-Facial Syndrome. J Ment Health Res Intellect Disabil (2009) 0.91
Familial expressed emotion: outcome and course of Israeli patients with schizophrenia. Schizophr Bull (2002) 0.91
Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia. J Clin Psychiatry (2003) 0.90
The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol (2004) 0.90
Admission rates of bipolar depressed patients increase during spring/summer and correlate with maximal environmental temperature. Bipolar Disord (2004) 0.90
Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study. Schizophr Res (2011) 0.90
Mirtazapine - a multifunctional drug: low dose for akathisia. CNS Spectr (2011) 0.90
Coping patterns as a valid presentation of the diversity of coping responses in schizophrenia patients. Psychiatry Res (2006) 0.89
Altered thermoregulation in ambulatory schizophrenia patients: a naturalistic study. World J Biol Psychiatry (2009) 0.89
Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial. Clin Neuropharmacol (2008) 0.89
An association of CAG repeats at the KCNN3 locus with symptom dimensions of schizophrenia. Biol Psychiatry (2002) 0.89
Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry (2003) 0.88
The 18-kDa translocator protein, formerly known as the peripheral-type benzodiazepine receptor, confers proapoptotic and antineoplastic effects in a human colorectal cancer cell line. Pharmacogenet Genomics (2008) 0.88
Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol (2003) 0.88
DHEA lessens depressive-like behavior via GABA-ergic modulation of the mesolimbic system. Neuropsychopharmacology (2008) 0.88
Enhanced cancer risk among patients with bipolar disorder. J Affect Disord (2007) 0.87
Emerging association between addictive gaming and attention-deficit/hyperactivity disorder. Curr Psychiatry Rep (2012) 0.87